Propose a title

Cochrane has guidelines for titles. The title should succinctly state the focus of the review, the intervention(s) reviewed and the problem at which the intervention is directed. Someone scanning the title should be able to decide quickly whether the review addresses their question of interest.

In most instances, a title should follow the structure "Intervention for condition". Other structures are described in the Style Guidelines for Cochrane Reviews. Specific outcomes are usually not included in the title; if they are, they should be listed as a subtitle separated by a colon from the main title. See the Cochrane Handbook for Systematic Reviews of Interventions for more details.

The Title Proposal Checklist and Forms for DTA reviews are available to download on our Forms page.

Topics

The scope of Cochrane Back and Neck (CBN) includes primary and secondary prevention and treatment of neck and back pain and other spinal disorders, excluding inflammatory diseases and fractures. The evidence is gathered from randomized controlled trials or from controlled clinical trials (RCTs) that compare one or more intervention groups to one or more comparison (control) groups.

Reviews examining interventions for fractures or inflammatory diseases are generally covered by the Cochrane Bone, Joint and Muscle Trauma Group and the Cochrane Musculoskeletal Group, respectively. CBN considers reviews covering the following areas to be within our scope.

The CBN Review Process

Please refer to the DTA Editorial Process and flowchart.

Review teams

To support the multinational, multidisciplinary spirit of Cochrane, improve the chances of completing and updating the review, and decrease the potential for bias, the review team should include at least three authors, who among them have expertise in methods of systematic reviews and the content area under review, and represent at least two nationalities. Preferably, teams should include authors from developing countries. Members of the review team who are also authors of included trials must not appraise the methodological quality or extract data from their own trials. They must state their authorship as a potential source of conflict.